Finance2 sources
Roche and Lilly report positive results for lung cancer treatments
- Roche's divarasib reduced the risk of death by 44% in a lung cancer trial.
- Lilly's olomorasib showed durable first-line activity in KRAS G12C-mutant non-small cell lung cancer.
- Both treatments were presented at ESMO 2026.
- The results are based on investigational treatments for lung cancer.
- The findings were reported by Reuters and the Financial Times.
Articles (4)
Reuters·
Roche says divarasib cut risk of death 44% in lung cancer trial
Financial Times·
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer – Company Announcement - FT.com
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer – Company Announcement - FT.com
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer – Company Announcement - FT.com